GSK bribery probe extends to Jordan and Lebanon; Novartis mistakenly announces approval of drug FDA has not yet ruled on;

@FiercePharma: Top-read special report yesterday: The top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma

@TracyStaton: Juicy trade-secrets dispute between Bristol-Myers + its ad agency and an account manager who jumped ship. Story via MediaPost | Follow @TracyStaton

@EricPFierce: Pacira invests $40M to $50M in a DPx U.K. plant, allowing it to produce an additional $300M in Exparel. Article via FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: So there are no anthropomorphized body parts in this week's FiercePharmaMarketing, but Viagra-flavored ice cream does make an appearance. Edition | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) says it's investigating bribery allegations in Jordan and Lebanon, following earlier claims of corruption in China, Iraq and Poland. Story

> Boehringer Ingelheim, joining other drugmakers in improving clinical trial transparency, says it will make its data available going back to 1998. Story

> Novartis ($NVS) accidentally sent out a mass email announcing the FDA approval of lung cancer drug Zykadia--a drug the agency has not actually approved yet. News

> The FDA wants drugmakers and others to weigh in on its ideas for its new strategy for health IT products. Blog post

> Teva ($TEVA) has launched a generic of Sunovion's insomnia treatment Lunesta. Report

Medical Device News

@FierceMedDev: Report: Cardiac Dimensions raises $20M for heart valve sales in Europe. Story | Follow @FierceMedDev

@VarunSaxena2: FierceBiotech broke story on Novartis stopping RNAi research. I'm interviewing Alnylam on fallout. $ALNY down 20+% since last week. | Follow @VarunSaxena2

@EmilyWFierce: Boston Scientific scores FDA approval for a new crop of implantable cardiac devices. News | Follow @EmilyWFierce

@MichaelGFierce: MIT team delivers three ovarian cancer drugs with one particle. Article via FierceDrugDelivery | Follow @MichaelGFierce

> St. Jude rides strong ICD sales to a first-quarter bump. More

> Qiagen puts up $10M to boost its diagnostics manufacturing. Piece

Biotech News

@FierceBiotech: Have the biotech bears run out of steam? Item | Follow @FierceBiotech

@JohnCFierce: Column Group nears goal line for $250M biotech venture fund. More | Follow @JohnCFierce

@DamianFierce: TriVascular's IPO prices at $12, below its range, and raises $78 million. Release | Follow @DamianFierce

@EmilyMFierce: ICYMI: Latest issue of FierceBiotech Research features 3-D printing to study cancer and Silly Putty to grow stem cells. More | Follow @EmilyMFierce

> Baxter's latest bleeding drug hits the mark in PhIII. Story

> BioAlliance and Topotarget plan to merge, pooling their cancer pipelines. More

> VCs gamble $96M on rare disease drug, biosimilar play and new drug for AMD. Article

Drug Delivery News

> Study shows nanoparticles can lose their uniform shape, size under lab conditions. More

> Alliqua pulls in $20M to support hydrogel wound care biz. Item

> MIT team delivers three ovarian cancer drugs with one particle. Story

> Magnetic anesthesia: Delivering nerve blocks locally with a targeted approach. Article

> Study: Inhalable encapsulated antibiotic from Aradigm kills 99% of infections. Report

> Alnylam COO on Novartis RNAi pullout: Big Pharma has 'never been able to innovate.' News

Diagnostics News

> Philips touts encouraging results from an early test of its hand-held cardiac blood Dx. More

> UCLA, working with a Chinese partner, will build a high-tech Dx lab in Shanghai. Story

> Qiagen licenses biomarker for rare blood disorders with a molecular Dx in mind. Article

> GE Healthcare's Dineen: A quest for new acquisitions will continue. News

> Sequenom scores a blow against Illumina in prenatal Dx patent fight. More

> An acquisition helps carry ERBA Diagnostics to a (small) 2013 profit. Item

Pharma Marketing News

> Pharma sales force took a hit in North America and Europe in 2013, new report shows. More

> BMS sues ex-account manager, claiming she took PD-1 marketing secrets to Merck agency. Story

> How to talk about constipation? Forest's new DTC campaign for Linzess will show you. Article

> Newly minted GlaxoSmithKline diabetes drug faces formidable foes in GLP-1 market. News

> Sanofi beefs up social media channels with Spanish Twitter push. Report

> GlaxoSmithKline bribery probe heats up as Polish prosecutors charge 13 people. Item

And Finally... Sanofi ($SNY) has brought on former WNBA star and coach Nancy Lieberman to help promote its OTC version of allergy med Nasacort, a move it says will help allergy sufferers "put the full 'cort press" on symptoms. Release

Editor's Note: An image in Monday's FiercePharma report should have shown GlaxoSmithKline's headquarters rather than AstraZeneca's to go along with this story. We regret the error and apologize for any confusion.

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.